USPSTF Updates Osteoporosis Screening Recommendations: What Changed in 2025
The U.S. Preventive Services Task Force reaffirmed screening for women 65+ and expanded guidance on risk assessment for younger postmenopausal women.
Read the original article at JAMAKairos™'s Take
Kairos™'s perspective on this story
In January 2025, the U.S. Preventive Services Task Force published its updated recommendation statement on osteoporosis screening to prevent fractures. The core guidance remains: screen all women aged 65 and older with DXA bone mineral density testing. For postmenopausal women younger than 65, screen those at increased fracture risk as determined by a validated clinical risk assessment tool. What changed is the strength and specificity of the supporting evidence — the accompanying systematic review included newer trial data, including the SCOOP screening trial, which demonstrated that community-based screening reduced hip fractures by 28%.
Notably, the USPSTF still concluded that evidence is insufficient to recommend for or against screening men. This leaves a significant clinical gap, given that roughly 2 million American men have osteoporosis and men account for nearly 30% of all hip fractures.
Why This Matters for Midlife Health
Screening guidelines define the clinical floor — the minimum that healthcare systems should be doing. But the midlife window between perimenopause and age 65 is exactly where proactive tracking can fill gaps that guidelines leave open. The USPSTF recommends risk assessment for postmenopausal women under 65, yet many primary care providers do not routinely perform it. Understanding your own risk factors — family history, early menopause, low body weight, smoking, prior fractures — and having them documented before your next visit can be the difference between getting screened at 55 and waiting until 65.
The Tracking Connection
Kairos™ is designed for exactly this kind of scenario: a user who is tracking menopausal symptoms, logging relevant lab work, and building a longitudinal health record that makes clinical risk factors visible at a glance. When you walk into an appointment with a documented timeline showing when symptoms started, what has changed, and what your risk profile looks like, your provider has the context to act on guidelines like these — even when the system defaults to waiting. Screening saves bones. Tracking ensures screening happens on time.
Ready to start tracking?
Kairos™ tracks, scores, and interprets the symptoms of midlife hormonal change — for both women and men.
Get StartedMore from the newsroom
SWAN Study: Bone Loss Accelerates Sharply During the Menopause Transition
The landmark SWAN longitudinal study showed that bone mineral density remains stable in early perimenopause but declines sharply in late perimenopause — about 2% per year — continuing into early postmenopause.
The FREEDOM Trial: Denosumab Reduces Vertebral Fractures by 68% in Postmenopausal Women
The landmark FREEDOM trial published in NEJM showed that denosumab, a monoclonal antibody, significantly reduced vertebral, hip, and nonvertebral fractures in women with osteoporosis over 3 years.
The Treatment Gap in Osteoporosis: Fewer Than 20% of High-Risk Patients Receive Care
A comprehensive review documents the growing osteoporosis treatment gap — with diagnosis rates below 20% and post-fracture treatment rates declining despite effective therapies being available.